This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
GEHC Expands Women's Health Portfolio With AI-Enabled Voluson
by Zacks Equity Research
GE HealthCare debuts AI-powered Voluson Performance ultrasound systems, enhancing women's health imaging with faster, smarter diagnostics.
GEHC Eyes icometrix Buyout to Strengthen Neurology Imaging Portfolio
by Zacks Equity Research
GE HealthCare moves to strengthen its neurology portfolio by acquiring icometrix, aiming to integrate AI-driven brain MRI solutions into its imaging platforms.
Is it a Prudent Move to Retain MYGN Stock in Your Portfolio Now?
by Zacks Equity Research
Myriad Genetics expands oncology testing and launches new diagnostics, but inflation and rising competition weigh on its outlook.
TEM Strengthens Radiology Portfolio With Pixel's FDA Clearance
by Sridatri Sarkar
Tempus AI secures FDA clearance for its updated Pixel cardiac imaging platform, boosting radiology precision and efficiency.
Hologic's Breast Health Rebound in Motion: How to Play the Stock Now?
by Moumi Mondal
HOLX's Breast Health revival, fueled by AI, leadership shifts and product upgrades, is setting up a growth rebound.
Here's Why You Should Add NVST Stock to Your Portfolio Right Now
by Zacks Equity Research
Envista's global expansion, strategic acquisitions, and solid solvency boost growth outlook despite FX headwinds.
Reasons to Add West Pharmaceutical Stock to Your Portfolio Now
by Zacks Equity Research
WST rides on GLP-1 demand and Annex 1 expansion, but margins face pressure from pricing and tariff headwinds.
Here's Why You Should Add PAHC Stock to Your Portfolio Right Now
by Zacks Equity Research
Phibro Animal Health posts strong Animal Health sales growth, aided by a Zoetis acquisition, while Mineral Nutrition and Performance Products rebound.
GEHC Stock Gains Following Launch of Revolution Vibe CT Imaging System
by Zacks Equity Research
GE HealthCare's FDA-cleared Revolution Vibe CT promises faster, AI-driven cardiac imaging with improved clarity, boosting efficiency and patient comfort.
GEHC or A: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
GEHC vs. A: Which Stock Is the Better Value Option?
GEHC Launches AI-Powered Vivid Pioneer Cardiac Ultrasound System
by Zacks Equity Research
GE HealthCare's Vivid Pioneer, cleared by CE Mark and FDA, brings AI-powered speed, precision and efficiency to cardiac imaging.
4 Medical Devices Behemoths to Buy Amid Extensive AI Applications
by Nalak Das
AI-driven innovations in medical devices are fueling growth for BSX, JNJ, GEHC and TEM.
GEHC Positioned for Growth With AI, Global Expansion and Margins
by Zacks Equity Research
GE HealthCare's Q2 results highlight revenue growth, AI-driven innovation, and global expansion with margin gains and strong demand.
GEHC or A: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
GEHC vs. A: Which Stock Is the Better Value Option?
New Strong Buy Stocks for August 15th
by Zacks Equity Research
TEN, ECO, MOS, GEHC and SBFG have been added to the Zacks Rank #1 (Strong Buy) List on August 15, 2025.
Hologic Eyes Organic Growth Rebound in 2026 on Breast Health Strength
by Moumi Mondal
HOLX targets a mid-single-digit organic growth rebound in 2026, powered by Breast Health recovery and new product innovation.
SRDX Stock Up Following Q3 Earnings Beat, Gross Margin Contracts
by Zacks Equity Research
Surmodics delivers third-quarter fiscal 2025 earnings beat with narrower loss, as revenue tops estimates despite lower SurVeil DCB sales.
Tutor Perini and Crocs have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Tutor Perini surges on a 386% earnings beat, record $21.1B backlog, and higher 2025 guidance, while Crocs struggles with tariff uncertainty.
Global Week Ahead: A China Trade Deadline & Ukraine Talks
by John Blank
Alongside all the geopolitical developments, this busy week also features a CPI report that may offer clearer insight into how tariffs are affecting U.S. inflation.
DOCS Stock Up in Pre-Market Post Q1 Earnings Beat, Gross Margin Down
by Zacks Equity Research
Doximity beats first-quarter fiscal 2026 estimates with double-digit revenue growth and lifts its full-year forecast.
AMN Stock Slips Despite Q2 Earnings & Revenue Beat, Margins Down
by Zacks Equity Research
AMN Healthcare tops second-quarter 2025 earnings and revenue forecasts, but margins and segment sales face continued pressure.
BD Stock Gains in Pre-Market Following Q3 Earnings Beat, Margins Up
by Zacks Equity Research
BDX tops third-quarter fiscal 2025 earnings and margin estimates, with strong results from its Medical and Interventional segments.
DaVita Stock Down Despite Q2 Earnings Beat, Gross Margin Expands
by Zacks Equity Research
DVA reports strong second-quarter 2025 results with earnings and revenue beat, along with a boost in gross margin, driven by core operations.
MASI Stock Slips Despite Q2 Earnings and Revenue Beat, Margins Expand
by Zacks Equity Research
Masimo's second-quarter 2025 performance beats earnings and revenue estimates, expands margins and lifts 2025 outlook.
Should You Buy, Sell or Hold Hologic Stock Post Q3 Earnings?
by Moumi Mondal
HOLX rises post earnings beat, fueled by Diagnostics strength and Surgical growth. However, macro headwinds persist.